Global Hereditary Angioedema Therapeutics Market Report 2024

Hereditary Angioedema Therapeutics Global Market Report 2024 – By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes), By Route of Administration (Intravenous, Subcutaneous, Oral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels), By Application (Prophylaxis, On-demand) – Market Size, Trends, And Global Forecast 2024-2033

Hereditary Angioedema Therapeutics Global Market Report 2024

Starting Price : $5000.00 | Pages : | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
FAQs
Customise Your Report
Request For Proposal
Request For Regional Data

Need assistance or more information before the purchase?

Enquire Before Buying
Hereditary Angioedema Therapeutics Global Market Report 2024

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Hereditary Angioedema Therapeutics Market Definition And Segments

Hereditary angioedema (HAE) therapeutics refers to therapy for an autosomal dominant condition brought on by a deficiency in or malfunction of the C1-inhibitor protein. Hereditary angioedema symptoms include angioedema-related upper airway, cutaneous, and, or gastrointestinal complaints.

The main drug classes of hereditary angioedema therapeutics are C1 esterase inhibitor, selective bradykinin B2 receptor antagonist, kallikrein inhibitor, others. C1 Esterase Inhibitor refers to a protein called that is present in the fluid portion of blood and it regulates the complement system's protein C1, which goes by the name of C1. The therapeutics are administered through intravenous, subcutaneous, and oral, distributed via hospital pharmacy, retail pharmacy, and others. The application of hereditary angioedema therapeutics include prophylaxis and on-demand.

The hereditary angioedema therapeutics market covered in this report is segmented –

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes

2) By Route of Administration: Intravenous, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

4) By Application: Prophylaxis, On-demand

The hereditary angioedema therapeutics market size has grown rapidly in recent years. It will grow from $5.74 billion in 2023 to $6.76 billion in 2024 at a compound annual growth rate (CAGR) of 17.6%. The growth in the historic period can be attributed to improved diagnosis and awareness, treatment access expansion, research and development initiatives, patient advocacy and education, and regulatory approvals.

The hereditary angioedema therapeutics market size is expected to see rapid growth in the next few years. It will grow to $13.47 billion in 2028 at a compound annual growth rate (CAGR) of 18.8%. The growth in the forecast period can be attributed to advancements in targeted therapies, global market expansion, gene therapy developments, personalized medicine trends, and collaboration in research and treatment. Major trends in the forecast period include global access initiatives, health economic outcomes research, early intervention strategies, and pediatric HAE therapeutics.

Surging Prevalence Of Hereditary Angioedema Ignites Growth In The Market

The rising prevalence of hereditary angioedema is expected to propel the growth of the hereditary angioedema market going forward. Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling of the skin and mucous membranes. The swelling is caused by excess fluid build-up (EDEMA) and can occur anywhere in the body, including the hands and feet, face, intestines, and airways. For Instance, in June 2022, according to Rare Disease Advisor, an online resource company that provides health care professionals, globally, 1 in every 50,000 persons suffer from hereditary angioedema with prevalence estimates ranging from 1:10,000 to 1:150,000. HAE episodes cause 15,000 to 30,000 emergency room visits each year in the US. 5.8% of cases of HAE had an average time to diagnosis of 0 to 6 months, whereas 5.8% had an average time to diagnosis of over 10 years. Therefore, the rising prevalence of hereditary angioedema is driving the growth of the hereditary angioedema market.

Elevated Healthcare Expenditure Propels Advancements In Hereditary Angioedema Therapeutics Market

The increasing healthcare expenditure is expected to boost the growth of the hereditary angioedema therapeutics market going forward. Healthcare expenditure refers to the total amount of resources, including financial resources, spent on healthcare goods and services within a specific period in a given geographical area. Greater healthcare expenditure allows for increased investment in research and development activities focused on understanding the underlying causes of hereditary angioedema and developing innovative therapeutic solutions. For instance, in March 2022, according to the 2021–2030 National Health Expenditure (NHE) report published by the Centers for Medicare & Medicaid Services, a US-based federal agency, the projected growth indicates that, on average, national health spending is expected to increase by 5.1% annually between 2021 and 2030, reaching a total of nearly $6.8 trillion. Additionally, it is anticipated that from 2021 to 2030, Medicare spending is going to rise at a 7.2% annual pace while Medicaid spending will rise at a 5.6% annual rate. Therefore, the increasing healthcare expenditure is driving the growth of the hereditary angioedema therapeutics market.

Major companies operating in the hereditary angioedema therapeutics market report are Shire PLC, Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca PLC, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.

Innovative Therapeutic Advancements Shape The Landscape Of Hereditary Angioedema Market

Product innovations are a key trend gaining popularity in the hereditary angioedema therapeutics market. Major companies operating in the hereditary angioedema therapeutics market are developing innovative products such as ligand-conjugated (LICA) investigational antisense medicine and gene therapy to sustain their position in the market. For Instance, in March 2023, Intellia Therapeutics, a US-based clinical-stage biotechnology company, launched an Investigational New Drug (IND) NTLA-2002, which was approved by the United States Food and Drug Administration for the treatment of hereditary angioedema. This enables the company's ongoing Phase 1/2 trial to include the US in the worldwide Phase 2 part. After a single dose of therapy, the inactivation of the target gene, kallikrein B1 (KLKB1), will permanently lower plasma kallikrein protein activity and prevent HAE attacks. NTLA-2002 is a candidate for in vivo genome editing.

Advancements In Hereditary Angioedema Therapeutics

Major companies operating in the hereditary angioedema therapeutics market are developing bradykinin B2 receptor antagonists to meet larger customer bases, more sales, and increase revenue. A bradykinin B2 receptor antagonist is a type of pharmaceutical agent that blocks or inhibits the activity of the bradykinin B2 receptor. For instance, in September 2021, Cycle Pharmaceuticals, a UK-based biotechnology company, launched SAJAZIR (icatibant) Injection, a United States Food and Drug Administration (FDA) approved treatment alternative for individuals suffering from Hereditary Angioedema (HAE). SAJAZIR (icatibant) Injection stands out as a bradykinin B2 receptor antagonist designed for the treatment of acute hereditary angioedema (HAE) attacks in adults aged 18 and above. Its distinctive feature lies in the convenience of a prefilled syringe, delivering a 30 mg dose of icatibant. Notably, patients have the capability to self-administer SAJAZIR subcutaneously, following appropriate training provided by a Healthcare Professional or a Registered Nurse from Cycle Vita, upon recognizing symptoms of an HAE attack.

Takeda Pharmaceutical Company Acquired Nimbus Lakshmi Inc.

In February 2023, Takeda Pharmaceutical Company, a Japan-based pharmaceutical company, acquired Nimbus Lakshmi Inc. from Nimbus Therapeutics LLC for an undisclosed amount. This acquisition strengthens Takeda's growing late-stage pipeline to expand its portfolio and patient impact across multiple indications and maintains strong global growth over the medium to long term. Nimbus Lakshmi, a fully-owned subsidiary of Nimbus Therapeutics, is a US-based company that provides Tyrosine kinase 2 (TYK2) inhibitor NDI-034858.

North America was the largest region in the global hereditary angioedema therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hereditary angioedema therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The hereditary angioedema therapeutics market includes revenues earned by entities by diagnosis and evaluation, treatment, and management of hereditary angioedema. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary angioedema therapeutics market also includes of sales of tranexamic acid, danazol, intravenous and subcutaneous nano-filtered purified plasma-derived human C1 esterase inhibitor concentrate, and lanadelumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The hereditary angioedema therapeutics market research report is one of a series of new reports from The Business Research Company that provides hereditary angioedema therapeutics market statistics, including hereditary angioedema therapeutics industry global market size, regional shares, competitors with a hereditary angioedema therapeutics market share, detailed hereditary angioedema therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the hereditary angioedema therapeutics industry. This hereditary angioedema therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hereditary Angioedema Therapeutics Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $6.76 billion
Revenue Forecast In 2033 $13.47 billion
Growth Rate CAGR of 18.8% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Prophylaxis, On-demand
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled Shire plc; Sanofi S.A.; Pharming Healthcare Inc.; Attune Pharmaceuticals Inc.; Adverum Biotechnologies Inc.; Arrowhead Pharmaceuticals Inc.; Ionis Pharmaceuticals Inc.; BioCryst Pharmaceuticals Inc.; CSL Behring LLC; KalVista Pharmaceutical Inc.; CENTOGENE N.V.; GlaxoSmithKline plc.; Eli Lilly and Company; Amgen Inc.; AbbVie Inc.; Incyte Corporation; BioMarin Pharmaceutical Inc.; Dyax Corp.; Salix Pharmaceuticals Inc.; Pharvaris N.V.; Innovent Biologics Inc.; AstraZeneca plc; BeiGene Ltd.; Jiangsu HenGrui Medicine Co. Ltd.; Bristol-Myers Squibb Company; F. Hoffmann-La Roche AG .; Exelixis Inc.; Lev Pharmaceuticals Inc.; Kedrion Biopharma Inc.; Pharos Pharmaceuticals Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Hereditary Angioedema Therapeutics Market Characteristics

    3. Hereditary Angioedema Therapeutics Market Trends And Strategies

    4. Hereditary Angioedema Therapeutics Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On the Market

    4.2. Ukraine-Russia War Impact On the Market

    4.3. COVID-19 Impact On the Market

    5. Global Hereditary Angioedema Therapeutics Market Size and Growth

    5.1. Global Hereditary Angioedema Therapeutics Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Hereditary Angioedema Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Hereditary Angioedema Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Hereditary Angioedema Therapeutics Market Segmentation

    6.1. Global Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    C1 Esterase Inhibitor

    Selective Bradykinin B2 Receptor Antagonist

    Kallikrein Inhibitor

    Other Drug Classes

    6.2. Global Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Intravenous

    Subcutaneous

    Oral

    6.3. Global Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospital Pharmacy

    Retail Pharmacy

    Other Distribution Channels

    6.4. Global Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Prophylaxis

    On-demand

    7. Hereditary Angioedema Therapeutics Market Regional And Country Analysis

    7.1. Global Hereditary Angioedema Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Hereditary Angioedema Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Hereditary Angioedema Therapeutics Market

    8.1. Asia-Pacific Hereditary Angioedema Therapeutics Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Hereditary Angioedema Therapeutics Market

    9.1. China Hereditary Angioedema Therapeutics Market Overview

    9.2. China Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Hereditary Angioedema Therapeutics Market

    10.1. India Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Hereditary Angioedema Therapeutics Market

    11.1. Japan Hereditary Angioedema Therapeutics Market Overview

    11.2. Japan Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Hereditary Angioedema Therapeutics Market

    12.1. Australia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Hereditary Angioedema Therapeutics Market

    13.1. Indonesia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Hereditary Angioedema Therapeutics Market

    14.1. South Korea Hereditary Angioedema Therapeutics Market Overview

    14.2. South Korea Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Hereditary Angioedema Therapeutics Market

    15.1. Western Europe Hereditary Angioedema Therapeutics Market Overview

    15.2. Western Europe Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Hereditary Angioedema Therapeutics Market

    16.1. UK Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Hereditary Angioedema Therapeutics Market

    17.1. Germany Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Hereditary Angioedema Therapeutics Market

    18.5. France Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Hereditary Angioedema Therapeutics Market

    19.9. Italy Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Hereditary Angioedema Therapeutics Market

    20.13. Spain Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Hereditary Angioedema Therapeutics Market

    21.1. Eastern Europe Hereditary Angioedema Therapeutics Market Overview

    21.2. Eastern Europe Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Hereditary Angioedema Therapeutics Market

    22.1. Russia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Hereditary Angioedema Therapeutics Market

    23.1. North America Hereditary Angioedema Therapeutics Market Overview

    23.2. North America Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Hereditary Angioedema Therapeutics Market

    24.1. USA Hereditary Angioedema Therapeutics Market Overview

    24.2. USA Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Hereditary Angioedema Therapeutics Market

    25.1. Canada Hereditary Angioedema Therapeutics Market Overview

    25.2. Canada Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Hereditary Angioedema Therapeutics Market

    26.1. South America Hereditary Angioedema Therapeutics Market Overview

    26.2. South America Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Hereditary Angioedema Therapeutics Market

    27.1. Brazil Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Hereditary Angioedema Therapeutics Market

    28.1. Middle East Hereditary Angioedema Therapeutics Market Overview

    28.2. Middle East Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Hereditary Angioedema Therapeutics Market

    29.1. Africa Hereditary Angioedema Therapeutics Market Overview

    29.2. Africa Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Hereditary Angioedema Therapeutics Market Competitive Landscape And Company Profiles

    30.1. Hereditary Angioedema Therapeutics Market Competitive Landscape

    30.2. Hereditary Angioedema Therapeutics Market Company Profiles

    30.2.1. Shire plc

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Sanofi S.A.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Pharming Healthcare Inc.

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Attune Pharmaceuticals Inc.

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Adverum Biotechnologies Inc.

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Global Hereditary Angioedema Therapeutics Market Competitive Benchmarking

    32. Global Hereditary Angioedema Therapeutics Market Competitive Dashboard

    33. Key Mergers And Acquisitions In The Hereditary Angioedema Therapeutics Market

    34. Hereditary Angioedema Therapeutics Market Future Outlook and Potential Analysis

    34.1 Hereditary Angioedema Therapeutics Market In 2028 - Countries Offering Most New Opportunities

    34.2 Hereditary Angioedema Therapeutics Market In 2028 - Segments Offering Most New Opportunities

    34.3 Hereditary Angioedema Therapeutics Market In 2028 - Growth Strategies

    34.3.1 Market Trend Based Strategies

    34.3.2 Competitor Strategies

    35. Appendix

    35.1. Abbreviations

    35.2. Currencies

    35.3. Historic And Forecast Inflation Rates

    35.4. Research Inquiries

    35.5. The Business Research Company

    35.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Hereditary Angioedema Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Global Hereditary Angioedema Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: China, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: India, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: France, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 75: Shire plc Financial Performance
  • Table 76: Sanofi S.A. Financial Performance
  • Table 77: Pharming Healthcare Inc. Financial Performance
  • Table 78: Attune Pharmaceuticals Inc. Financial Performance
  • Table 79: Adverum Biotechnologies Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Hereditary Angioedema Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Global Hereditary Angioedema Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: China, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: India, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: France, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 75: Shire plc Financial Performance
  • Figure 76: Sanofi S.A. Financial Performance
  • Figure 77: Pharming Healthcare Inc. Financial Performance
  • Figure 78: Attune Pharmaceuticals Inc. Financial Performance
  • Figure 79: Adverum Biotechnologies Inc. Financial Performance
Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company
Read More
Global Gene Therapy Market 2022 – Market Opportunities And Strategies
Read More
The Microbiome Market Share, Market Size, And Growth Rate 2022
Read More
Latest TNF Alpha Inhibitors Market Growth Study 2022-2026 By The Business Research Company
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the dermatitis market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth
Read More
Cold Pain Therapy Global Market Report 2024 – By Product (OTC Products, Prescription Products), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, E- Pharmacies), By Application (Musculoskeletal Disorders, Post-operative Therapy, Sports Injuries, Post-trauma Therapy) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Physical Therapy Software Global Market Report 2024 – By Terminal Type( PC Terminal, Mobile Terminal), By Deployment( On-Premise, Cloud), By Application( Hospitals, Clinics, Others Applications ) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Vitamin D Therapy Global Market Report 2024 – By Administration( Oral, Parenteral), By Purchasing( OTC Drugs, Prescription Drugs), By Age Group( Children, Adults, Senior Adults), By Application( Osteoporosis, Rickets, Skin Diseases, Muscle Weakness, Autoimmune Disorders) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Online Therapy Services Global Market Report 2024 – By Type (Cognitive Behavioral Therapy, Psychodynamic Therapy, Personal Centered Therapy), By Tool (Email, Mobile Device Apps, Real-Time Instant Messaging, Telephone, Video Conferencing), By Application (Residential Use, Commercial) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Targeted Therapy Global Market Report 2024 – By Type (Small Molecule Medicines, Monoclonal Antibodies), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Lymphoma, Renal Cancer, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Chemotherapy Global Market Report 2024 – By Product Type (Pump, Cannula, Catheter, Other Product Types), By Service (Blood Cancer, Throat Cancer, Lung Cancer, Ovarian Cancer, Stomach Cancer), By Drugs (Alkylating Agents, Antimetabolites, Anti-Tumor Antibiotics, Topoisomerase Inhibitors, Mitotic Inhibitors, Other Drugs), By Route Of Administration (Oral, Intravenous), By End User (Hospitals, Research Institutes, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Testosterone Replacement Therapy Global Market Report 2024 – By Product Type (Oral, Implants, Gel Or Creams, Patches, Buccal Adhesive, Parenteral, Other Products), By Indication (Hypogonadism, Autoimmune Conditions, Genetic Disorders, Sex Organ Surgeries, Other Indications), By Active Ingredient Type (Testosterone, Methyl Testosterone, Testosterone Undecanoate, Testosterone Enanthate, Testosterone Cypionate), By End User (Hospitals, Clinics, Other End-User) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Hormone Therapy Global Market Report 2024 – By Therapy (Estrogen Hormone Replacement, Growth Hormone Replacement, Thyroid Hormone Replacement, Testosterone Replacement), By Route of Administration (Oral, Parenteral, Other Routes of Administration), By Indication (Menopause, Hypothyroidism, Growth Hormone Deficiency, Other Indications), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies And Stores, Online Pharmacies) – Market Size, Trends, And Global Forecast 2024-2033
View Report

Frequently Asked Questions

What is the definition of the hereditary angioedema therapeutics market?

Hereditary angioedema (HAE) therapeutics refers to therapy for an autosomal dominant condition brought on by a deficiency in or malfunction of the C1-inhibitor protein. Hereditary angioedema symptoms include angioedema-related upper airway, cutaneous, and, or gastrointestinal complaints. For further insights on the hereditary angioedema therapeutics market, request a sample here

How will the hereditary angioedema therapeutics market drivers and restraints affect the hereditary angioedema therapeutics market dynamics? What forces will shape the hereditary angioedema therapeutics industry going forward?

The hereditary angioedema therapeutics market major growth driver - surging prevalence of hereditary angioedema ignites growth in the market. For further insights on the hereditary angioedema therapeutics market, request a sample here

What is the forecast market size or the forecast market value of the hereditary angioedema therapeutics market ?

The hereditary angioedema therapeutics market size has grown rapidly in recent years. It will grow from $5.74 billion in 2023 to $6.76 billion in 2024 at a compound annual growth rate (CAGR) of 17.6%. The growth in the historic period can be attributed to improved diagnosis and awareness, treatment access expansion, research and development initiatives, patient advocacy and education, regulatory approvals.. The hereditary angioedema therapeutics market size is expected to see rapid growth in the next few years. It will grow to $13.47 billion in 2028 at a compound annual growth rate (CAGR) of 18.8%. The growth in the forecast period can be attributed to advancements in targeted therapies, global market expansion, gene therapy developments, personalized medicine trends, collaboration in research and treatment.. Major trends in the forecast period include global access initiatives, health economic outcomes research, early intervention strategies, pediatric hae therapeutics.. For further insights on the hereditary angioedema therapeutics market, request a sample here

How is the hereditary angioedema therapeutics market segmented?

The hereditary angioedema therapeutics market is segmented
1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Prophylaxis, On-demandFor further insights on the hereditary angioedema therapeutics market, request a sample here

Which region has the largest share of the hereditary angioedema therapeutics market? What are the other regions covered in the report?

North America was the largest region in the global hereditary angioedema therapeutics market in 2023. Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the hereditary angioedema therapeutics market, request a sample here.

Who are the major players in the hereditary angioedema therapeutics market?

Major companies operating in the hereditary angioedema therapeutics market report are Shire plc, Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc. For further insights on the hereditary angioedema therapeutics market, request a sample here.

What are the key trends in the hereditary angioedema therapeutics market?

Major trend in the hereditary angioedema therapeutics market - innovative therapeutic advancements shape the landscape of hereditary angioedema market. For further insights on the hereditary angioedema therapeutics market, request a sample here.

What are the major opportunities in the hereditary angioedema therapeutics market? What are the strategies for the hereditary angioedema therapeutics market?

For detailed insights on the major opportunities and strategies in the hereditary angioedema therapeutics market, request a sample here.

How does the hereditary angioedema therapeutics market relate to the overall economy and other similar markets?

For detailed insights on hereditary angioedema therapeutics market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the hereditary angioedema therapeutics industry?

For detailed insights on the mergers and acquisitions in the hereditary angioedema therapeutics industry, request a sample here.

What are the key dynamics influencing the hereditary angioedema therapeutics market growth? SWOT analysis of the hereditary angioedema therapeutics market.

For detailed insights on the key dynamics influencing the hereditary angioedema therapeutics market growth and SWOT analysis of the hereditary angioedema therapeutics industry, request a sample here.